Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
0.8816
+0.0439 (5.24%)
At close: Feb 27, 2026, 4:00 PM EST
0.8400
-0.0416 (-4.72%)
After-hours: Feb 27, 2026, 7:40 PM EST
Pasithea Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
20.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 15.06K | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKTTA News
- 2 days ago - Pasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript - Seeking Alpha
- 12 days ago - Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 6 weeks ago - Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study - GlobeNewsWire